Fig. 1From: Genomically personalized therapy in head and neck cancerGenomically driven dysregulated pathways and potential matched therapies in HNSCC. Combination strategies currently being tested in ongoing clinical trials are also shown. Abbreviations: MAB, monoclonal antibody; TKI, tyrosine kinase inhibitorBack to article page